Sanofi: to present data at EADV Congress
(CercleFinance.com) - The company is presenting late-breaking Phase III data at the EADV 2022 Congress showing that Dupixent (dupilumab) significantly improves the signs and symptoms of nodular prurigo.
At 24 weeks, nearly three times as many patients treated with Dupixent showed a clinically significant reduction in itching and skin lesions compared to those treated with placebo.
Sanofi said that there is currently no drug approved specifically for the treatment of nodular prurigo; the US submission is under priority review; the EU submission is under review.
The group will present 22 abstracts on Dupixent at the European Academy of Dermatology and Venereology (EADV) 2022 Congress on four dermatological diseases with a type 2 inflammatory signature.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
At 24 weeks, nearly three times as many patients treated with Dupixent showed a clinically significant reduction in itching and skin lesions compared to those treated with placebo.
Sanofi said that there is currently no drug approved specifically for the treatment of nodular prurigo; the US submission is under priority review; the EU submission is under review.
The group will present 22 abstracts on Dupixent at the European Academy of Dermatology and Venereology (EADV) 2022 Congress on four dermatological diseases with a type 2 inflammatory signature.
Copyright (c) 2022 CercleFinance.com. All rights reserved.